FDA Approves Bosutinib for Pediatric Chronic Myelogenous Leukemia

News
Article

Based on findings from the phase 1/2 BCHILD trial, the FDA approved bosutinib for pediatric chronic myelogenous leukemia.

Findings from the phase 1/2 BCHILD study (NCT04258943)—in which 28 patients with PH-positive resistant or intolerant CML and 21 patients with newly diagnosed, chronic phase disease received bosutinib—supported the approval.

Findings from the phase 1/2 BCHILD study (NCT04258943)—in which 28 patients with PH-positive resistant or intolerant CML and 21 patients with newly diagnosed, chronic phase disease received bosutinib—supported the approval.

The FDA has granted approval to bosutinib (Bosulif) for the treatment of pediatric patients aged 1 year or older with newly diagnosed or resistant/previous treatment intolerant chronic myelogenous leukemia (CML) that is Philadelphia chromosome (Ph) positive and in chronic phase, according to a press release from the FDA.1

Findings from the phase 1/2 BCHILD study (NCT04258943)—in which 28 patients with PH-positive resistant or intolerant CML were treated with 300 mg/m2 to 400 mg/m2 and 21 patients with newly diagnosed, chronic phase disease received 300 mg/m2—supported the approval.2 The recommended doses were 400 mg/m2 and 300 mg/m2, respectively.

In the newly diagnosed population, the major cytogenetic response rate was (MCyR) was 76.2% (95% CI, 52.8%-91.8%) and the complete cytogenetic response rate (CCyR) was 71.4% (95% CI, 47.8%-88.7%). Additionally, investigators reported a major molecular response (MMR) rate of 28.6% (95% CI, 11.3%-52.3%) with a median duration of response of 14.2 months (range, 1.1-26.3).

In the resistant/intolerant population, the MCyR and CCyR rates were 82.1% (95% CI, 63.1%-93.9%) and 78.6% (95% CI, 59.0%-91.7%), respectively. Moreover, investigators reported an MMR of 50.0% (95% CI, 30.6%-69.4%) in this population. Of 14 patients, 2 lost an MMR following 13.6 months and 24.7 months of treatment with bosutinib, respectively. The median follow-up was 23.2 months (range, 1-61.5 months).

In terms of safety, frequent adverse effects included diarrhea, abdominal pain, vomiting, nausea, rash, fatigue, hepatic dysfunction, headache, pyrexia, decreased appetite, and constipation. Additionally, investigators reported several frequent laboratory abnormalities, including increased creatinine, increased alanine aminotransferase or aspartate aminotransferase, decreased white blood cell count, and decreased platelet count.

References

  1. FDA approves bosutinib for pediatric patients with chronic myelogenous leukemia. News release. FDA. September 26, 2023. Accessed September 27, 2023. https://bit.ly/46madME
  2. Pennesi E, Brivio E, Willemse ME, et al. Preliminary results from the first-in-child phase II trial (ITCC-054/COG-AAML1921) of bosutinib in pediatric patients with newly diagnosed (ND) chronic myeloid leukemia (CML). J Clin Oncol. 2023; 41(supp 16):10017. doi:10.1200/JCO.2023.41.16_suppl.10017
Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
A 2-way communication between providers and patients may help facilitate dose modifications to help better manage adverse effects.
Treatment with AML depends on a variety of factors, including stage of treatment, transplant eligibility, and mutational status.
The medical characteristics of a patient may heavily factor into the selection of tyrosine kinase inhibition for the treatment of chronic myeloid leukemia.
Related Content
Clinical Implications Remain After Dasatinib CRL in CML/ALL

Clinical Implications Remain After Dasatinib CRL in CML/ALL

Ariana Pelosci
October 28th 2025
Article

The FDA's CRL for the HyNap formulation of dasatinib due to manufacturing issues does not affect the efficacy or availability of standard dasatinib.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Results from the phase 1/2 AUGMENT-101 trial support the FDA’s decision for approving revumenib in this NPM1-mutated, relapsed/refractory AML population.

FDA Approves Revumenib in R/R NPM1-Mutant AML

Tim Cortese
October 24th 2025
Article

Results from the phase 1/2 AUGMENT-101 trial support the FDA’s decision for approving revumenib in this NPM1-mutated, relapsed/refractory AML population.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

FDA Issues CRL for Dasatinib in CML/ALL

FDA Issues CRL for Dasatinib in CML/ALL

Ariana Pelosci
October 20th 2025
Article

Based on the Good Manufacturing Practice observations, the FDA has given a complete response letter for dasatinib for patients with CML/ALL.

A 13-week Good Laboratory Practice toxicity study demonstrated that UB-VV111 was well-tolerated in CD34-humanized mice.

FDA Grants Fast Track Designation to UB-VV111 in Select B-Cell Malignancies

Tim Cortese
October 1st 2025
Article

A phase 1 trial is evaluating UB-VV111 with and without rapamycin as treatment for patients with CLL and LBCL who received at least 2 prior therapies.